Consolidated Statement of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total Revenues	$ 135,000	$ 163,000
Costs and Expenses:
Production costs	850,000	806,000
Research and development	7,672,000	5,720,000
General and administrative	8,672,000	8,654,000
Impairment of assets	1,779,000	135,000
Total Costs and Expenses	18,973,000	15,315,000
Operating loss	(18,838,000)	(15,152,000)
Gain (loss) on investments	(201,000)	219,000
Interest expense and other finance costs	(67,000)	(672,000)
Extinguishment of financing obligation and note payable	(2,701,000)	142,000
Gain on sale of fixed assets	216,000
Redeemable warrants valuation adjustment	145,000	(123,000)
Gain from sale of income tax operating losses	2,319,000	1,186,000
Net Loss	(19,127,000)	(14,400,000)
Other comprehensive loss
Reclassification adjustment for realized investment loss	376,000
Change in unrealized loss on marketable securities available for sale	(329,000)	(47,000)
Net comprehensive loss	$ (19,080,000)	$ (14,447,000)
Basic and diluted loss per share	$ (0.40)	$ (0.45)
Weighted average shares outstanding basic and diluted	47,339,975	31,842,799
Clinical Treatment Programs U S [Member]
Revenues:
Total Revenues	$ 135,000	$ 144,000
Clinical Treatment Programs Europe [Member]
Revenues:
Total Revenues		$ 19,000